Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study.

Jamie Lopez BernalNick AndrewsCharlotte GowerChris RobertsonJulia StoweElise TessierRuth SimmonsSimon CottrellRichard RobertsMark O'DohertyKevin BrownClaire CameronDiane StocktonJim McMenaminMary Ramsay

Published in: BMJ (Clinical research ed.) (2021)

Vaccination with either one dose of BNT162b2 or ChAdOx1-S was associated with a significant reduction in symptomatic covid-19 in older adults, and with further protection against severe disease. Both vaccines showed similar effects. Protection was maintained for the duration of follow-up (>6 weeks). A second dose of BNT162b2 was associated with further protection against symptomatic disease. A clear effect of the vaccines against the B.1.1.7 variant was found.

Keyphrases

coronavirus disease
sars cov
physical activity
randomized controlled trial
systematic review
early onset
type diabetes
depressive symptoms
sleep quality